Nasdaq

Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023

– Plenary session oral presentation: Monday, April 17, 2023, 10:15 a.m.-12:15 p.m. ET– Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023, 1:30-5 ...
Yahoo Finance

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length ...
Yahoo Finance

Merus updates on Petosemtamab+Pembrolizumab data in HNSCC

Merus (MRUS) N.V. "announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These ...
Mena FN

Merus’ Petosemtamab Monotherapy Interim Data Continues To Demonstrate Clinically Meaningful Activity In 2L+ R/M HNSCC

(MENAFN- GlobeNewsWire - Nasdaq) Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025 Petosemtamab in mCRC evaluation ...
Nasdaq

Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...
Mena FN

Merus’ Petosemtamab With Pembrolizumab Interim Data Demonstrates Robust Efficacy And Durability In 1L PD-L1+ R/M HNSCC

- Conference Call on Thursday, May 22 at 5:30 p.m. ET “By essentially every metric, we believe these interim data are significantly better than pembrolizumab monotherapy, the control arm of our ...
Finanznachrichten

Merus N.V.: Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

BTD is supported by updated data from the ongoing phase 1/2 open-label, multicenter trial evaluating petosemtamab in combination with pembrolizumab in 1L HNSCC expressing PD-L1 (May 28, 2024). In the ...
Stockhouse

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...
manilatimes

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

"By essentially every metric, we believe these interim data are significantly better than pembrolizumab monotherapy, the control arm of our ongoing phase 3 trial, and underscores the opportunity ...
Yahoo Finance

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...